No Data
No Data
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
J.P. Morgan analyst Anupam Rama maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $64 to $57.According to TipRanks data, the analyst has a success
Sobi and Enable Injections Announce Agreement to Develop and Distribute Aspaveli in Combination With EnFuse in Sobi Territories
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $66 to $61.According to TipRanks data, the analyst has a
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now